Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer - Trial NCT06205485
Access comprehensive clinical trial information for NCT06205485 through Pure Global AI's free database. This Phase 3 trial is sponsored by Canadian Cancer Trials Group and is currently Not yet recruiting. The study focuses on Rectal Cancer. Target enrollment is 250 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Canadian Cancer Trials Group
Timeline & Enrollment
Phase 3
Mar 30, 2024
Jun 30, 2030
Primary Outcome
Clinical response rate upon re-staging,Quality of Life defined using the LARS score
Summary
This study is being done to answer the following questions: Is the chance of rectal cancer
 responding the same if chemotherapy alone is given before limited surgery compared to
 chemotherapy and radiation therapy given together before limited surgery? If radiation
 therapy is not given, is quality of life better?
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06205485
Non-Device Trial